Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design. 2007

Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
Structural Bioinformatics, BIOTEC TU Dresden, Tatzberg 47-51, 01307, Dresden, Germany. jens.laettig@biotec.tu-dresden.de

The human secretory phospholipase A2 group IIA (PLA2-IIA) is a lipolytic enzyme. Its inhibition leads to a decrease in eicosanoids levels and, thereby, to reduced inflammation. Therefore, PLA2-IIA is of high pharmacological interest in treatment of chronic diseases such as asthma and rheumatoid arthritis. Quercetin and naringenin, amongst other flavonoids, are known for their anti-inflammatory activity by modulation of enzymes of the arachidonic acid cascade. However, the mechanism by which flavonoids inhibit Phospholipase A2 (PLA2) remained unclear so far. Flavonoids are widely produced in plant tissues and, thereby, suitable targets for pharmaceutical extractions and chemical syntheses. Our work focuses on understanding the binding modes of flavonoids to PLA2, their inhibition mechanism and the rationale to modify them to obtain potent and specific inhibitors. Our computational and experimental studies focused on a set of 24 compounds including natural flavonoids and naringenin-based derivatives. Experimental results on PLA2-inhibition showed good inhibitory activity for quercetin, kaempferol, and galangin, but relatively poor for naringenin. Several naringenin derivatives were synthesized and tested for affinity and inhibitory activity improvement. 6-(1,1-dimethylallyl)naringenin revealed comparable PLA2 inhibition to quercetin-like compounds. We characterized the binding mode of these compounds and the determinants for their affinity, selectivity, and inhibitory potency. Based on our results, we suggest C(6) as the most promising position of the flavonoid scaffold to introduce chemical modifications to improve affinity, selectivity, and inhibition of PLA2-IIA by flavonoids.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013816 Thermodynamics A rigorously mathematical analysis of energy relationships (heat, work, temperature, and equilibrium). It describes systems whose states are determined by thermal parameters, such as temperature, in addition to mechanical and electromagnetic parameters. (From Hawley's Condensed Chemical Dictionary, 12th ed) Thermodynamic
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D017076 Computer-Aided Design The use of computers for designing and/or manufacturing of anything, including drugs, surgical procedures, orthotics, and prosthetics. CAD-CAM,Computer-Aided Manufacturing,Computer-Assisted Design,Computer-Assisted Manufacturing,Computer Aided Design,Computer Aided Manufacturing,Computer Assisted Design,Computer Assisted Manufacturing,Computer-Aided Designs,Computer-Assisted Designs,Design, Computer-Aided,Design, Computer-Assisted,Designs, Computer-Aided,Designs, Computer-Assisted,Manufacturing, Computer-Aided,Manufacturing, Computer-Assisted
D054497 Phospholipases A2, Secretory A subcategory of phospholipases A2 that are secreted from cells. They are 14 kDa proteins containing multiple disulfide-bonds and access their substrate via an interfacial binding site that interacts with phospholipid membranes. In addition specific PHOSPHOLIPASE A2 RECEPTORS can bind to and internalize the enzymes. Secreted Phospholipase A2,sPLA2,Phospholipases A2, Secreted,SPLA2 Phospholipases,Secreted Phospholipases A2,Secretory Phospholipase A2,sPLA(2),sPLA2s,A2, Secreted Phospholipase,Phospholipase A2, Secreted,Phospholipase A2, Secretory,Phospholipases, SPLA2,Secretory Phospholipases A2

Related Publications

Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
April 1994, European journal of biochemistry,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
March 1993, Agents and actions,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
September 1998, The Journal of biological chemistry,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
May 1996, Biochimica et biophysica acta,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
June 1997, Inflammation,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
January 2009, International archives of allergy and immunology,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
August 2004, Biological & pharmaceutical bulletin,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
December 2010, Current opinion in lipidology,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
February 2009, Planta medica,
Jens Lättig, and Markus Böhl, and Petra Fischer, and Sandra Tischer, and Claudia Tietböhl, and Mario Menschikowski, and Herwig O Gutzeit, and Peter Metz, and M Teresa Pisabarro
December 1988, Agents and actions,
Copied contents to your clipboard!